Skip to main content
. 2020 Nov 13;45(1):13–28. doi: 10.3892/or.2020.7851

Figure 1.

Figure 1.

Structural formula of approved ALK-TKIs. (A) Crizotinib, (B) ceritinib, (C) brigatinib, (D) alectinib, (E) lorlatinib and (F) entrectinib. ALK-TKIs, anaplastic lymphoma kinase tyrosine kinase inhibitors.